Beactica Therapeutics Advances Lead Candidate for Hard-to-Treat Cancers

Unlike traditional therapies that merely block binding pockets, BEA-28 removes TEAD transcription factors entirely, effectively shutting down the signaling pathways that drive tumor growth and immune evasion. In preclinical trials, the compound demonstrated robust tumor regression and successfully restored sensitivity to KRAS inhibitors in resistant cellular models. According to CEO Dr. Per Källblad, the decision to advance the molecule followed the successful completion of rigorous pharmacological and pharmacokinetic benchmarks.

Beactica will now transition the project into final candidate validation, which includes non-regulatory toxicology and advanced formulation profiling. The company intends to deploy a biomarker-led strategy to identify patients most likely to respond to the treatment, specifically targeting KRAS-driven cancers and mesothelioma. While the candidate has shown promise in xenograft models at well-tolerated daily doses, it remains an investigational agent pending further clinical validation.